Optic complications among hospitalized patients with RA, SLE, and SpA were linked to poor outcomes and higher health care costs, especially among Black and Asian patients.

DelveInsight's 'Systemic Lupus Erythematosus Pipeline Insight 2024' report provides comprehensive global coverage of pipeline ...

SAN DIEGO, Nov. 11, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to ...

Fate Therapeutics, Inc. FATE presented encouraging initial clinical and translational data from the first patient treated in ...

Phase 3 trial of Biogen and UCB's dapirolizumab pegol shows significant improvement in lupus disease activity. Read more here ...

After the unexpected success of their PHOENYCS GO study for dapirolizumab pegol in lupus earlier this fall, Biogen and UCB ...

Long-term treatment with anifrolumab significantly reduced the rate of organ damage compared with SOC among patients with SLE ...

Discover six bispecific antibody companies developing a two-in-one approach to delivering targeted therapeutics to patients.

Cellular immunotherapy specialist Fate Therapeutics soared as much as 73%, and closed up 12.45 at $2.27 yesterday, after it ...

Initial Clinical Data from Phase 1 Autoimmunity Study of FT819 1XX CAR T-cell Product Candidate to be Presented in 4Q24; ...

11, according to a statement. Fate said it is also enrolling a second treatment arm under the Phase 1 Autoimmunity study to ...

系统性红斑狼疮（SLE）是风湿免疫科的常见疾病，也是历届ACR年会的热议焦点之一。本次年会上，SLE领域的前沿进展依然备受瞩目。本文梳理了本次大会SLE领域部分精粹，以飨读者。